Background: AUR in BPH (benign prostatic hyperplasia) patients is is not an uncommon presentation in our tertiary care hospital. Most of the studies regarding the use of alpha blockers have been conducted using alfuzosin and other older alpha blockers. Under this background present study was carried out to assess the efficacy of silodosin (a highly selective alpha blocker) in the management of these AUR patients. Materials and Methods: This prospective study was conducted over a period of 4 years in the unit-II of the Postgraduate Department of General Surgery of SMHS (Shri Maharaja Harisingh) hospital, an associated hospital of Govt. medical college Srinagar, from January 2014 to December 2017). Patients were randomized to two groups- 1 and 2. Each group comprised of thirty-one patients with similar clinical and demographic variables.
Objective: The aim of the present study was to assess the efficacy of silodosin in the management of AUR in BPH (benign prostatic hyperplasia) patients.
Results: Age of patients ranged from 57 to 87 years with a mean age of 68.54 years. Equal number of patients were included in both the groups (group 1 and group 2). Baseline patient demographic and clinical characteristics were similar in the two groups. Successful TWOC was observed in 74.2% of the patients in group 1 and in 41.9% of the patients in group 2 (p value =0.010). Thus Group 1 has statistically significant higher success rate of TWOC as compared to group 2.
Conclusion: Silodosin appears to be effective treatment modality for managing the first time AUR in patients with BPH (benign prostatic hyperplasia).